Trial ID 20318 | Maryland Oncology Hematology Trial ID 20318 – Maryland Oncology Hematology

Trial ID 20318

Trial Information - Phase III

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Protocol ID: 849-010

Sponsor: Mirati Therapeutics Inc.

Status: PENDING STAR

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Colorectal

Status

PENDING STAR

Sponsor

Mirati Therapeutics Inc.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology